Documento fuente o registro público

FDA 510(k) K220963 — Simplexa COVID-19 & Flu A/B Direct

FDA 510(k) index record K220963. Device: Simplexa COVID-19 & Flu A/B Direct. Applicant as listed: Diasorin Molecular, LLC. Decision date: 2023-03-17.

OtherU.S. Food and Drug Administration (FDA)2023-03-17

Fuente

"device_name": "Simplexa COVID-19 & Flu A/B Direct"

Esta entrada describe lo que cubre el documento; el propio documento es la autoridad. Incluirlo no implica estar de acuerdo con sus conclusiones.

Review and references

Reviewer

Automated FDA record verification

Published

2026-10-20

Updated

2026-10-29

Disclaimer

professional use

FDA 510(k) public index record K220963.

Device name: Simplexa COVID-19 & Flu A/B Direct. Applicant as listed: Diasorin Molecular, LLC.

Decision date: 2023-03-17. Decision wording: Substantially Equivalent.

Product code: QOF. Regulation: 21 CFR 866.3981. Medical specialty: Microbiology.

This page reproduces regulator index metadata. The applicant field identifies the submitter and is not a manufacturer identity check. Consult the original FDA record for the decision and associated documents; this index does not verify current commercial availability or clinical performance.

Interested in these solutions?

Submit a sourcing request with the assays, volumes, and timeline of your own project.

Explorar más